Asset profile
SHR-1918
Monoclonal antibody
Evidence outlook · registrational
Registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-10.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Competitive landscape
10 competitors in this universe: 0 direct rivals (same mechanism and indication), 10 same-class, 0 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| SHR-1918: this drug | Phase 3 | Monoclonal antibody | ANGPTL3 | ||
| Evinacumab (Evkeeza) | Phase 3 | Monoclonal antibody | ANGPTL3 | ||
| ALN-ANG3 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | ||
| BW-00112 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | ||
| EDP167 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | ||
| HRS-7249 | Phase 2 | Unknown Undisclosed | ANGPTL3 | ||
| Solbinsiran | Phase 2 | RNA / oligonucleotide | ANGPTL3 | ||
| SYH2070 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | ||
| AZD1705 | Phase 1 | Small molecule | ANGPTL3 | ||
| CTX310 | Phase 1 | Gene therapy / editing | ANGPTL3 | ||
| NNC0491-6075 | Phase 1 | Unknown Undisclosed | ANGPTL3 |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (3)
June 2027 (1)
What to watch
October 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (1)
July 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.